Welcome, Guest. Please login or register.
June 06, 2020, 03:18:15 pm

Login with username, password and session length


  • Total Members: 105
  • Latest: harryQ
  • Total Posts: 283
  • Total Topics: 144
  • Online Today: 19
  • Online Ever: 518
  • (January 21, 2020, 05:24:49 pm)
Users Online
Users: 0
Guests: 8
Total: 8


Welcome to the Cancer Health Forums, a round-the-clock discussion area for people who have any type of cancer, their friends and family and others with questions about living with cancer. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Cancer Health Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Immunotherapy Shows Promise for Hard-to-Treat Breast Cancer  (Read 856 times)

Offline Cancer Health Editors

  • Jr. Member
  • **
  • Posts: 56
    • View Profile
First-line treatment with the checkpoint inhibitor Tecentriq (atezolizumab) plus chemotherapy reduced the risk of disease progression or death for women with metastatic or locally advanced triple-negative breast cancer (TNBC), according to late-stage clinical trial results recently announced by Genentech, a Roche company.

Interim study data also showed an “encouraging” overall survival benefit for a subset of women with a favorable biomarker, the company said. These results have not yet been presented at a scientific conference or published in a medical journal.

The findings come from the IMpassion130 trial, a Phase III randomized, double-blind study evaluating the safety and efficacy of Tecentriq plus Abraxane (nab-paclitaxel), an albumin-bound formulation of the widely used chemotherapy drug, for patients with locally advanced or metastatic (spread beyond the breast) TNBC.



© 2020 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.